ContraFect Corporation (Nasdaq:
CFRX), a clinical-stage biotechnology company focused on
the discovery and development of direct lytic agents (DLAs),
including lysins and amurin peptides, as new medical modalities for
the treatment of life-threatening, antibiotic-resistant infections,
announces today that the Company has been selected for an oral
presentation and three poster presentations at the 33rd European
Congress of Clinical Microbiology & Infectious Diseases
(ECCMID) Annual Meeting to be held from April 15-18, 2023 in
Copenhagen, Denmark. The data being presented will feature both
exebacase and CF-370, the Company’s lead product candidates with
CF-370 demonstrating potent in vitro bactericidal activity against
drug-resistant pathogens, including multi-drug resistant (MDR) and
extensively drug-resistant (XDR) strains.
ECCMID 2023 Presentation
Details:
ORAL PRESENTATION:
Title: Efficacy of lysin CF-370 in
addition to amikacin in a neutropenic rabbit lung infection model
caused by an extensively drug-resistant (XDR) P.
aeruginosaPresenting Author: Mark Pulse,
University of North Texas Health Science Center, College of
PharmacyPresentation Date and Location: April 15,
2023, Arena 4Session Time: 3:30am
ETAbstract ID# 02033
POSTER PRESENTATIONS:
Title: Activity of lysin CF-370 at the cell
envelope of Gram-negative (GN) ESKAPE pathogens revealed by
electron microscopySession Date and Location:
April 17, 2023, Poster areaSession Time: 6:00am ET
Poster P2120; Abstract ID #05341
Title: Bacteriolytic and anti-virulence
activities of engineered lysin CF-370 against Gram-negative (GN)
ESKAPE pathogensSession Date and Location: April
17, 2023, Poster areaSession Time: 6:00am ET
Poster P2141; Abstract ID #05336
Title: Lysin exebacase exerts potent in vitro
bactericidal activity against Staphylococcus aureus strains
associated with pulmonary exacerbations (PExs) of cystic fibrosis
(CF)Session Date and Location: April 17, 2023,
Poster areaSession Time: 6:00am ET Poster
P2175; Abstract ID #05345
All posters will be available to meeting registrants on demand
through the ECCMID website.
Following the meeting, the presentations will be available on
the ContraFect website.
About ContraFect
ContraFect is a biotechnology company focused on
the discovery and development of DLAs, including lysins and amurin
peptides, as new medical modalities for the treatment of
life-threatening, antibiotic-resistant infections. An estimated
700,000 deaths worldwide each year are attributed to
antimicrobial-resistant infections. We intend to address life
threatening infections using our therapeutic product candidates
from our platform of DLAs, which include lysins and amurin
peptides. Lysins are a new class of DLAs which are recombinantly
produced antimicrobial proteins with a novel mechanism of action
associated with the rapid killing of target bacteria, eradication
of biofilms and synergy with conventional antibiotics. Amurin
peptides are a novel class of DLAs which exhibit broad-spectrum
activity against a wide range of antibiotic-resistant Gram-negative
pathogens, including P. aeruginosa, Acinetobacter
baumannii, and Enterobacter species. We believe that the
properties of our lysins and amurin peptides will make them
suitable for targeting antibiotic-resistant organisms, such as MRSA
and P. aeruginosa, which can cause serious infections such as
bacteremia, pneumonia and osteomyelitis. We have completed a Phase
2 clinical trial for the treatment of Staph
aureus bacteremia, including endocarditis, with our lead lysin
candidate, exebacase, which is the first lysin to enter clinical
studies in the U.S. Exebacase was granted Breakthrough Therapy
designation by the FDA for the treatment of MRSA bloodstream
infections, including right-sided endocarditis, when used in
addition to SOC anti-staphylococcal antibiotics.
Follow ContraFect on Twitter
@ContraFectCorp and
LinkedIn.
Forward-Looking Statements
This press release contains, and our officers
and representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities laws.
Forward-looking statements can be identified by words such as
“projects,” “may,” “will,” “could,” “would,” “should,” “believes,”
“expects,” “anticipates,” “estimates,” “intends,” “plans,”
“potential,” “promise” or similar references to future periods.
Examples of forward-looking statements in this release include,
without limitation, statements regarding: the ECCMID presentations,
data presented, and statements made regarding the same, CF-370
attributes, ContraFect’s ability to discover and develop DLAs as
new medical modalities for the treatment of life-threatening,
antibiotic-resistant infections, whether ContraFect will address
life-threatening infections using therapeutic candidates from its
DLA platform, whether lysins are a new class of DLAs which are
recombinantly produced, antimicrobial proteins with a novel
mechanism of action associated with the rapid killing of target
bacteria, eradication of biofilms and synergy with conventional
antibiotics, whether amurins are a novel class of DLAs which
exhibit broad-spectrum activity against a wide range of
antibiotic-resistant Gram-negative pathogens, and whether the
properties of ContraFect’s lysins and amurins will make them
suitable for targeting antibiotic-resistant organisms, such as MRSA
and P. aeruginosa. Forward-looking statements are statements that
are not historical facts, nor assurances of future performance.
Instead, they are based on ContraFect’s current beliefs,
expectations and assumptions regarding the future of its business,
future plans, strategies, projections, anticipated events and
trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent risks, uncertainties and changes in circumstances that
are difficult to predict and many of which are beyond ContraFect’s
control, including, without limitation, that ContraFect has and
expects to continue to incur significant losses, ContraFect’s need
for additional funding, which may not be available, the occurrence
of any adverse events related to the discovery, development and
commercialization of ContraFect’s product candidates such as
unfavorable clinical trial results, insufficient supplies of drug
products, the lack of regulatory approval, or the unsuccessful
attainment or maintenance of patent protection, changes in
management may negatively affect ContraFect’s business and other
important risks detailed under the caption “Risk Factors” in
ContraFect's Annual Report on Form 10-K for the year ended December
31, 2022 and its other filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in the
forward-looking statements. Any forward-looking statement made by
ContraFect in this press release is based only on information
currently available and speaks only as of the date on which it is
made. Except as required by applicable law, ContraFect expressly
disclaims any obligations to publicly update any forward-looking
statements, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
Investor Relations
Contacts:
Michael MessingerContraFect CorporationTel:
914-207-2300Email: mmessinger@contrafect.com
Grafico Azioni ContraFect (NASDAQ:CFRX)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni ContraFect (NASDAQ:CFRX)
Storico
Da Giu 2023 a Giu 2024